Sessile serrated adenoma/polyp (SSA/p) is a precancerous lesion, and its differential diagnosis from hyperplastic polyp (HP) could be challenging in certain circumstances based on morphology alone. Hes1 is a downstream target of Notchsignaling pathway and plays an important role in intestinal development by regulating differentiation of enterocytes. In this study, we evaluated the expression patterns of Hes1 in SSA/p and HP, and determine whether Hes1 immunostaining can help differentiate between these 2 entities. Serrated polyps with cytologic dysplasia (SSA with cytologic dysplasia, tubular adenoma, and traditional serrated adenoma) were also studied. Hes1 is ubiquitously expressed in the nuclei of normal colon epithelial cells. The complete loss or a very weak expression of Hes1 is observed in the majority of the SSA/p in the study (58/ 63, 92%) compared with the normal expression of Hes1 in HP (35/35,100%). In SSA/p with cytologic dysplasia, dysplastic area demonstrated cytoplasmic and/or nuclear staining for Hes1. Tubular adenoma and traditional serrated adenoma showed variability of Hes1 staining within the polyp with a mixed positive and negative staining pattern. Our study suggests that loss of Hes1 could be used as a sensitive and specific marker to differentiate SSA/p from HP, which helps the diagnosis in morphologically challenging cases.
S essile serrated adenoma/polyp (SSA/p) is a recently recognized precursor lesion for colorectal carcinoma, mostly located in the right side of the colon (cecum, as-cending colon, and transverse colon). 1 The detailed diagnostic criteria have also been evolved since the establishment of this diagnostic entity. Two to 3 contiguous SSA/p-type crypts are sufficient for the diagnosis of SSA/p according to the fourth edition of the WHO Classification of Tumors of the Digestive System, 2 whereas the 2012 consensus meeting recommend that serrated polyps with as few as 1 SSA-type crypt should be diagnosed as SSA/p. 3 Sometimes being limited by the size, orientation, and other biopsy artifacts, the differential diagnosis of SSA/p from hyperplastic polyp (HP) could be morphologically challenging based on the histology only. Especially, in the left colon, prolapse colonic mucosa can mimic SSA/p, which has been recognized and described by Huang et al. 4 Interobserver agreement for the diagnosis of SSA/p has been moderate based on hematoxylin and eosin staining. 5 The distinction between SSA/p and HP is clinically important because they have different recommended surveillance interval based on their apparently different cancer risk. 6 A sensitive and specific marker for SSA/p would be helpful to diagnose morphologically challenging cases. Biomarkers for SSA/p have been explored and studied. MUC6 has been reported to be expressed in SSA/p but not in HP. 7 However, MUC6 was found to lack specificity for SSA/p in another study. 8 The immunohistochemistry (IHC) scoring of annexin A10, encoded by ANXA10, was reported to carry a sensitivity of 73% and specificity of 95% in the diagnosis of SSA/p. 9 Ideal biomarkers with both high sensitivity and specificity are still lacking.
Notch signaling plays essential functions in intestinal development and homeostasis. Hes1 is a wellknown downstream target of Notch-signaling pathway and plays an important role in intestinal development by regulating differentiation of enterocytes. Hes1 is expressed in the nuclei of epithelial cells of the intestine in both human and mice, and its expression has been shown to be increased in adenoma and colon adenocarcinoma. 10 The expression of Hes1 is also shown associated with the differentiation of colon adenocarcinoma, with a stronger expression of Hes1 represented in poorly differentiated adenocarcinoma. 11 However, the expression of Hes1 in colon adenocarcinoma shown in the literature is not consistent. In a paper published by Fre et al, 12 Hes1 is strongly expressed in adenomas but not expressed in 14 cases of human colon adenocarcinomas, indicating that loss of Hes1 could be associated with carcinogenic transformation of adenoma. A study performed by Ueo et al 13 showed that in intestinal-specific Hes1 knockout mice, greatly expanded crypts were observed in the colon by 2 months of age. Our own studies of an animal model with genetic defects in Notch signaling indicate that suppressed Hes1 expression in this model is associated with the development of SSA/p-like polyps and then adenocarcinoma in mouse colon (unpublished data). On the basis of our own findings and reports from others, we speculated that loss of Hes1 can be a promising marker for SSA/p. Here in this study, we have studied Hes1 expression in SSA/p and HP as well as other serrated polyps, including SSA/p with cytologic dysplasia, traditional serrated adenoma (TSA) and tubular adenoma (TA).
MATERIALS AND METHODS

Sample Collection
Hematoxylin and eosin-stained sections from a single tertiary care medical center were reviewed. All the colon biopsies were performed from 2013 to 2014. All specimens analyzed were formalin-fixed and paraffinembedded tissue sections. All the cases were reviewed by the junior pathologist, and then independently reviewed by 2 gastrointestinal subspecialty practicing pathologists. Only the cases with consensus diagnosis among 3 pathologists were included in the study. A total of 63 SSA/p (41 to 81 y old, mean age 62.3 y, male/female ratio 1.0) and 35 HP (39 to 85 y old, mean age 62.6 y, male/female ratio 1.2) were selected. Among the 63 SSA/p cases, 45 were biopsies from the right colon (cecum and ascending colon), and 18 were from the left colon (descending colon, sigmoid colon, and rectum). For the 35 HP, 27 were from the left colon and 8 were from the right colon. The HPs were subdivided into the microvesicular subtype (n = 28) and the goblet cell-rich subtype (n = 7) based on mucin distribution. 1 No mucin-poor HP was included in the study. Fifteen TAs, 10 TSA, and 3 SSA/p with dysplasia were included in the study, respectively. The study was approved by the Institutional Research Board of the University Hospitals Case Medical Center. Written consent was waived as the study was carried on discarded tissues and involves chart-review only.
IHC Staining of Hes1
Expression of Hes1 was evaluated by IHC on all cases included in this study. The IHC was performed by the Immunohistochemistry Diagnostic Laboratory of University Hospitals Case Medical Center. Tissue slides were processed using a BenchMark Ultra automated immunostainer (Ventana, Tucson, AZ). Slides were deparaffinized, antigen retrieved with standard Cell Conditioning 1 (Ventana Medical Systems, AZ), a tris-based buffer pH 8.3 solution for 64 minutes at 951C, then incubated at 371C with the primary antibody HES1 rabbit monoclonal (1:200 dilution, Catalog #2922-1, clone EPR4226 from Epitomics, CA, part of Abcam, Cambridge, MA) for 24 minutes. Detection was performed with Ultraview-DAB from Ventana and subsequently counterstained.
Statistical Analysis
Comparison of the Hes1 expression rates among HP and SSA/p was done using the Fisher exact test (2-tailed).
RESULTS
Hes1 Expression in Normal Colon and HP
As shown in Figures 1A and B , in normal colonic mucosa, Hes1 IHC demonstrated consistent nuclei staining in surface epithelial cells, crypt cells, and interstitial inflammatory cells in the lamina propria. We observed strong and consistent nuclear staining in the interstitial inflammatory cells in the lamina propria in every case in this study. It is interpred as positive if the Hes1 staining intensity is comparable to that of the laminar propria inflammatory cells. In HP cases, nuclei staining of Hes1 was maintained in the crypts in both microvesicular (28/28, 100%, Figs. 1C-F) and goblet cell (7/7, 100%, Figs. 1G, H) HPs. The staining intensity is comparable to normal colon mucosa. The nuclear expression of Hes1 was also maintained in the distorted crypts of HP with prolapse mucosa (Fig. 2 ).
Hes1 Expression in SSA/p and SSA With Dysplasia
As shown in Figures 3A-F , loss of or very weak Hes1 expression in the crypts was identified in the majority of SSA/p cases studied (53/58). There are 5 SSAs with positive nuclei staining in the crypts, all located in the left colon (3 in sigmoid colon and 2 in rectums, images not shown). A summary of the Hes1 IHC results of HP and SSA/p according to the sites of the polyps is provided in Table 1 . There is a significant difference (P < 0.001) in positive Hes1 staining for HP and SSA/p when comparison is performed based either on the diagnosis (SSA vs. HP), or based on the site of polyps (left-sided SSA vs. HP, right-sided SSA vs. HP).
Hes1 has a unique staining pattern in SSA with cytologic dysplasia. Instead of showing a complete loss or very weak staining in the nuclei, it displays a diffuse positive staining in the cytoplasm in the dysplastic epithelium (Figs. 3G, H ). This staining pattern was observed in all cases of SSA with dysplasia.
Hes1 Expression in TA and TSA
In our study, Hes1 expression in TA was variable within the polyp, with mostly robust positive nuclear staining but loss of Hes1 expression in some patchy areas (Figs. 4A, B) . In TSA, Hes1 expression also showed a mixed pattern within the polyp, with focal strong nuclear staining and focal loss of expression ( Figs. 4C, D) . The staining of Hes1 in the lamina propria cells in these polyps was uniform and robust. Hes1, in differentiating SSA/p from HP. As shown in Table 1 , loss of Hes1 expression has a sensitivity of 92% and specificity of 100% in differentiating SSA/p from HP. HP with mucosal prolapse is recognized to be a mimicker of SSA. Our study showed that nuclear staining of Hes1 is maintained in the distorted crypts of this condition. Therefore, the immunostaining of Hes1 could be particularly helpful to diagnose polyps from sites prone to mucosal prolapse condition. We confirmed the reported finding that Hes1 is normally expressed in the nuclei of epithelium of colorectal mucosa. We also observed a strong nuclear expression of Hes1 in interstitial inflammatory cells in lamina propria, which can serve as a universal internal positive control and reference level for each specimen. The nuclear staining pattern is also a favorable factor for interpretation compared with the cytoplasmic staining.
A small number of polyps in this study located in the left colon have morphology consistent with SSA/p but show positive nuclear staining of Hes1. This suggests 2 possibilities: one possibility is that the left-sided SSA/p could maintain Hes1 expression, whereas right-sided SSA/p normally shows uniform loss of Hes1. It has been reported that distinct genetic and epigenetic features exist in the proximal SSA/p and the distal SSA/p. 14 Another possibility is that these left-sided polyps are in fact HPs with morphology indiscernible from SSA/p due to various factors (such as orientation, processing artifact, etc.). Further study with more definitive standard is needed to clarify this issue, as the current biomarkers such as BRAF mutation is not specific enough to distinguish SSA/p from HP. 15 Hes1 is shown to be associated with secretory lineage differentiation of intestinal epithelial cells. 13 It is unclear yet at which level (transcriptional or translational) the downregulation of Hes1 takes place in the SSA/p. If it occurs at the transcriptional level, the consistent expression of Hes1 in interstitial inflammatory cells in lamina propria would make it difficult to identify Hes1 as a differentially expressed genes by cDNA microarray approach or methylation study using an entire polyp. An in situ RNA hybridization would be helpful to clarify whether downregulation of Hes1 in SSA/p is regulated transcriptionally; however, this is beyond the scope of the current study which focuses on the IHC staining of Hes1.
TA and TSA are common malignancy precursors encountered in colorectal biopsies. Although not the focus of this study, we evaluated limited number of cases to gain basic knowledge of Hes1 staining pattern in these polyps. TA has upregulated Hes1 expression according to previous reports. We have observed a mixed staining pattern in the cases we studied, with mostly positive nuclear staining and some focal negative staining shown for TA, and mixed staining pattern for TSA. Given that there is a robust and uniform staining of Hes1 in lamina propria inflammatory cells, the mixed staining pattern is unlikely to be an artifact. This is consistent with the notion that TA is an epigenetically diverse population. 16 TSA has also been shown to be a genetically heterogenous group, with both KRAS and BRAF mutations commonly identified. 17 Interestingly, in the dysplastic epithelium of SSA/p, we observed a diffuse positive staining of Hes1 in the cytoplasm suggestive of altered location of Hes1 and hence possible dysregulation of Hes1 signaling. We speculate that this finding may be related to genetic and/ or epigenetic changes with SSA progression to SSA with dysplasia, and more in-depth study would be needed to investigate the underlying mechanism. The distinction between these 3 types of adenomas with cytologic dysplasia could potentially be helped by Hes1 IHC based on the unique staining pattern of dysplastic portion of SSA, although a more extensive study with larger number of cases included in each category would be needed before we could reach the conclusion.
CONCLUSIONS
In this study, we found that Hes1 expression is either completely lost or shows weak staining in SSA/p compared with HP or normal colonic mucosa. Loss of Hes1 has the potential as a useful marker for diagnosing SSA/p in morphologically challenging cases. We also observed that Hes1 expression is switched to positive cytoplasmic staining in dysplastic epithelium in SSA/p with cytologic dysplasia. TA and TSA showed variable Hes1 staining within the polyp with a mixed positive and negative staining pattern in nuclei.
